BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

789 related articles for article (PubMed ID: 32700586)

  • 21. Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG).
    Rattanathammethee T; Norasetthada L; Bunworasate U; Wudhikarn K; Julamanee J; Noiperm P; Lanamtieng T; Phiphitaporn P; Navinpipat M; Kanya P; Jit-Ueakul D; Wongkhantee S; Suwannathen T; Chaloemwong J; Wong P; Makruasi N; Khuhapinant A; Prayongratana K; Niparuck P; Kanitsap N; Suwanban T; Intragumtornchai T
    Ann Hematol; 2023 Jul; 102(7):1887-1895. PubMed ID: 37202499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world.
    Vodicka P; Benesova K; Janikova A; Prochazka V; Belada D; Mocikova H; Steinerova K; Duras J; Karban J; Hanackova V; Sykorova A; Obr A; Trneny M
    Eur J Haematol; 2022 Aug; 109(2):162-165. PubMed ID: 35502609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis.
    Smith SD; Lopedote P; Samara Y; Mei M; Herrera AF; Winter AM; Hill BT; Shadman M; Ujjani C; Lynch RC; Jacobson CA; Kim AI; Caimi P; Milano F; Gopal AK
    Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):170-175. PubMed ID: 33431309
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Current status and future prospects of diffuse large B-cell lymphoma treatment].
    Yamaguchi M
    Rinsho Ketsueki; 2022; 63(9):1126-1134. PubMed ID: 36198538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study.
    Deng R; Gibiansky L; Lu T; Flowers CR; Sehn LH; Liu Q; Agarwal P; Liao MZ; Dere R; Lee C; Man G; Hirata J; Li C; Miles D
    CPT Pharmacometrics Syst Pharmacol; 2024 Jun; 13(6):1055-1066. PubMed ID: 38622879
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
    Dere RC; Beardsley RL; Lu D; Lu T; Ku GH; Man G; Nguyen V; Kaur S
    Front Immunol; 2023; 14():1119510. PubMed ID: 37063860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polatuzumab Vedotin: First Global Approval.
    Deeks ED
    Drugs; 2019 Sep; 79(13):1467-1475. PubMed ID: 31352604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
    Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
    Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma.
    Patel KK; Isufi I; Kothari S; Foss F; Huntington S
    Leuk Lymphoma; 2020 Dec; 61(14):3387-3394. PubMed ID: 32835553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas.
    Dimou M; Papageorgiou SG; Stavroyianni N; Katodritou E; Tsirogianni M; Kalpadakis C; Banti A; Arapaki M; Iliakis T; Bouzani M; Verrou E; Spanoudakis E; Giannouli S; Marinakis T; Mandala E; Mparmparousi D; Sachanas S; Dalekou-Tsolakou M; Hatzimichael E; Vadikolia C; Violaki V; Poziopoulos C; Tsirkinidis P; Chatzileontiadou S; Vervessou E; Ximeri M; Sioni A; Konstantinidou P; Kyrtsonis MC; Siakantaris MP; Angelopoulou MK; Pappa V; Konstantopoulos K; Panayiotidis P; Vassilakopoulos TP
    Hematol Oncol; 2021 Aug; 39(3):336-348. PubMed ID: 33583077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical pharmacology strategies to accelerate the development of polatuzumab vedotin and summary of key findings.
    Liao MZ; Lu D; Lu T; Gibiansky L; Deng R; Samineni D; Dere R; Lin A; Hirata J; Shen BQ; Zhang D; Li D; Li C; Miles D
    Adv Drug Deliv Rev; 2024 Apr; 207():115193. PubMed ID: 38311111
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma.
    Kawasaki N; Nishito Y; Yoshimura Y; Yoshiura S
    Br J Haematol; 2022 Oct; 199(2):245-255. PubMed ID: 35764309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma.
    Vijenthira A; Kuruvilla J; Crump M; Jain M; Prica A
    J Clin Oncol; 2023 Mar; 41(8):1577-1589. PubMed ID: 36315922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.
    Cordoba R; Prawitz T; Westley T; Sharma A; Ambarkhane S; Kapetanakis V; Sabatelli L
    Adv Ther; 2022 Jun; 39(6):2668-2687. PubMed ID: 35403948
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polatuzumab vedotin pharmacokinetics in a hemodialysis patient with diffuse large B-cell lymphoma.
    Yasuda H; Kaga N; Taka H; Ochiai T; Yamana T; Miura Y; Ishii M; Sasaki M; Ando J; Ando M
    Cancer Chemother Pharmacol; 2024 Mar; 93(3):265-268. PubMed ID: 37750932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma.
    Yuen S; Phillips TJ; Bannerji R; Marlton P; Gritti G; Seymour JF; Johnston A; Arthur C; Dodero A; Sharma S; Hirata J; Musick L; Flowers CR
    Am J Hematol; 2024 Jul; 99(7):1281-1289. PubMed ID: 38700035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B Cell Lymphoma.
    Thuresson PO; Vander Velde N; Gupta P; Talbot J
    Adv Ther; 2020 Dec; 37(12):4877-4893. PubMed ID: 33001384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. US cost-effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma.
    Betts KA; Thuresson PO; Felizzi F; Du EX; Dieye I; Li J; Schulz M; Masaquel AS
    J Comp Eff Res; 2020 Oct; 9(14):1003-1015. PubMed ID: 33028076
    [No Abstract]   [Full Text] [Related]  

  • 39. Spotlight on polatuzumab vedotin: new standards for diffuse large B-cell lymphoma?
    Ghione P; Salles G
    Haematologica; 2024 May; ():. PubMed ID: 38813707
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin.
    Li D; Lee D; Dere RC; Zheng B; Yu SF; Fuh FK; Kozak KR; Chung S; Bumbaca Yadav D; Nazzal D; Danilenko D; Go MAT; Williams M; Polson AG; Poon KA; Prabhu S
    Br J Pharmacol; 2019 Oct; 176(19):3805-3818. PubMed ID: 31270798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.